Edgewise Therapeutics, Inc.

NASDAQ:EWTX

Biotechnology

Healthcare
$41.37 +3.19%

+$1.11 today

Market cap
$4.45B
Beta
0.30
P/E (TTM)
-21.9
EPS (TTM)
-$1.64
52W Low $12.15High $40.77

Volume 0.87M

Average 1.32M

EWTX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Edgewise Therapeutics, Inc.NASDAQ: EWTX

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue remains negative

Q3 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $590K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $147.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$2.27M— YoY
LTMSep 2026
$590K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
2.27M USD
Year-over-year change
—

Cost of Revenue vs competitors

How EWTX compares with its peers on the latest reported figures

  • EWTX's LTM Sep 2026 cost of revenue of $590K is the 8th highest of the 10 companies compared; the peer median is $3.09M.
EWTX Competitors Peer median
Cost of Revenue for EWTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$821.4M +102.3%+84.7%37.6%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$180.19M +250.5%+17.1%17.9%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$42.41M -26.6%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.05M ——698.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$3.09M +178.5%—9.6%
PEPGPepGen Inc.LTM Mar 2026$1.72M +351.6%——
SLDBSolid Biosciences Inc.LTM Mar 2026$781K +91.9%——
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$590K ———
DYNDyne Therapeutics, Inc.LTM Jun 2026$521K ———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding EWTX) $3.09M+140.4%+50.9%27.7%

Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00002.27M
Gross Profit0000(2.27M)
Gross Margin—————
Research & Development32.19M54.03M90.91M126.97M151.39M
Selling, General & Admin11.03M17.63M23.45M31.87M40.02M
Operating Expenses43.22M71.66M114.36M158.83M189.14M
Depreciation & Amortization272K538K1.73M2.29M2.27M
EBITDA(42.54M)(63.08M)(98.43M)(131.52M)(165.53M)
EBITDA Margin—————
Operating Income(43.22M)(71.66M)(114.36M)(158.83M)(191.41M)
Operating Margin—————
Interest Income402K2.66M14.19M25.02M23.61M
Interest Expense04.02M000
Other Income / Expenses402K4.02M14.19M25.02M23.61M
Income Before Tax(42.81M)(67.64M)(100.16M)(133.81M)(167.8M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(42.81M)(67.64M)(100.16M)(133.81M)(167.8M)
Net Margin—————
EPS (Basic)(0.86)(1.26)(1.57)(1.45)(1.63)
EPS (Diluted)(0.86)(1.26)(1.57)(1.45)(1.63)
Weighted Avg Shares49.5M53.59M63.72M92.41M102.93M
Weighted Avg Shares (Diluted)49.5M53.59M63.72M92.41M102.93M

Edgewise Therapeutics, Inc.

NASDAQ:EWTX

Intrinsic Alpha fair value

Locked

Current Price

$41.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.